Catabasis Pharmaceuticals Current Assets

Catabasis Pharmaceuticals posts a current assets of $250M as of September 2025. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Current Assets is one piece of Catabasis Pharmaceuticals's financial statement story. At $250M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CATB's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Catabasis Pharmaceuticals's other metric pages and overview cover the third.

Judging Catabasis Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $250M here, then scan peer and history charts to see if the gap is persistent.